HF
IRD

Hoxton Financial’s Opus Genetics IRD Stock Holding History

Hoxton Financial’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		$0 Sell
1
-1
-50% -$166 ﹤0.01% 377
2015
Q4 		$0 Hold
2
– – ﹤0.01% 387
2015
Q3 		$0 Hold
2
– – ﹤0.01% 379
2015
Q2 		$0 Buy
2
+1
+100% +$340 ﹤0.01% 365
2015
Q1 		$0 Hold
1
– – ﹤0.01% 357
2014
Q4 		$0 Buy
+1
New +$345 ﹤0.01% 370

Other funds holding IRD

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HVIA
Hudson Valley Investment Advisors Goshen, New York $823M AUM 31.4% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Hoxton Financial's IRD Position: Q1 2016 in Review

Hoxton Financial reduced its Opus Genetics (IRD) stake by 50% in Q1 2016, selling an estimated $166 and leaving 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #377.

Hoxton Financial first reported a position in IRD in Q4 2014 and has held it in 6 quarters since. 36 funds tracked by Wall St. Rank hold IRD as of Q1 2016.

  • Hoxton Financial held 1 share of Opus Genetics worth $0 as of Q1 2016.
  • Hoxton Financial sold 1 Opus Genetics share in Q1 2016, an estimated $166.
  • Opus Genetics made up ﹤0.01% of Hoxton Financial's portfolio in Q1 2016, its #377 holding.
  • Hoxton Financial first reported a position in Opus Genetics in Q4 2014 and has held it in 6 quarters since.
  • 36 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2016.

Based on Hoxton Financial's 13F filing for Q1 2016, filed 29 Apr 2016.